Gibson Dunn & Crutcher advised Calumet, Inc. on the transaction, and Chapman and Cutler advised the underwriters. Calumet, Inc. (NASDAQ: CLMT) (the “Company” or “Calumet”) and...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher is advising Goldman Sachs & Co. LLC and Barclays Capital Inc. on the offering. LandBridge Company announced the private placement of $200...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP served as legal advisor to the Partnership and Lazard acted as financial advisor to the Partnership. On November 21, 2023, USD...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is advising Calumet Specialty Products Partners, L.P. on the transaction. Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) announced the execution of an...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is advising Calumet Specialty Products Partners, L.P. on its offering. Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) (the “Partnership” or “Calumet”) and...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP acted for Valaris Limited on the offering and the revolving credit facility. Valaris Limited (NYSE: VAL) and its wholly-owned subsidiary, Valaris Finance...
You must be a Standard 1 Year member to access this content.
